IS6426A - Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni - Google Patents

Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni

Info

Publication number
IS6426A
IS6426A IS6426A IS6426A IS6426A IS 6426 A IS6426 A IS 6426A IS 6426 A IS6426 A IS 6426A IS 6426 A IS6426 A IS 6426A IS 6426 A IS6426 A IS 6426A
Authority
IS
Iceland
Prior art keywords
piperazinomethylbenzamide
delta
receptor agonist
opioid receptor
compounds
Prior art date
Application number
IS6426A
Other languages
English (en)
Other versions
IS2143B (is
Inventor
Brown William
Walpole Christopher
Plobeck Niklas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS6426A publication Critical patent/IS6426A/is
Publication of IS2143B publication Critical patent/IS2143B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Valve-Gear Or Valve Arrangements (AREA)
  • Liquid Crystal (AREA)
  • Furan Compounds (AREA)
IS6426A 1999-12-20 2002-06-18 Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni IS2143B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904674A SE9904674D0 (sv) 1999-12-20 1999-12-20 Novel compounds
PCT/SE2000/002562 WO2001046174A1 (en) 1999-12-20 2000-12-15 Novel compounds

Publications (2)

Publication Number Publication Date
IS6426A true IS6426A (is) 2002-06-18
IS2143B IS2143B (is) 2006-09-15

Family

ID=20418210

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6426A IS2143B (is) 1999-12-20 2002-06-18 Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni

Country Status (31)

Country Link
US (2) US6680318B2 (is)
EP (1) EP1242410B1 (is)
JP (1) JP2003522741A (is)
KR (2) KR100769814B1 (is)
CN (1) CN1608064A (is)
AT (1) ATE275143T1 (is)
AU (1) AU780799B2 (is)
BG (1) BG65457B1 (is)
BR (1) BR0016591A (is)
CA (1) CA2395300A1 (is)
CZ (1) CZ20022124A3 (is)
DE (1) DE60013486T2 (is)
DK (1) DK1242410T3 (is)
EE (1) EE200200337A (is)
ES (1) ES2225289T3 (is)
HK (1) HK1048308B (is)
HU (1) HUP0300020A3 (is)
IL (2) IL150125A0 (is)
IS (1) IS2143B (is)
MX (1) MXPA02006063A (is)
NO (1) NO322432B1 (is)
NZ (1) NZ519986A (is)
PL (1) PL356780A1 (is)
PT (1) PT1242410E (is)
RU (1) RU2258703C2 (is)
SE (1) SE9904674D0 (is)
SI (1) SI1242410T1 (is)
SK (1) SK8832002A3 (is)
UA (1) UA71650C2 (is)
WO (1) WO2001046174A1 (is)
ZA (1) ZA200204255B (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040067950A1 (en) * 1998-07-27 2004-04-08 Schering-Plough Corporation High affinity ligands for nociceptin receptor ORL-1
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
NZ539828A (en) * 2001-05-18 2007-01-26 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL371297A1 (en) * 2001-10-29 2005-06-13 Ardent Pharmaceuticals, Inc. Method of treating depression with delta receptor agonist compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
CN1890208A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
SE0400027D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
MX2007001240A (es) 2004-08-02 2007-03-23 Astrazeneca Ab Derivados de diarilmetil-piperazina, preparaciones y usos de las mismas.
SE0401968D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
CN101128447A (zh) * 2005-02-28 2008-02-20 阿斯利康(瑞典)有限公司 二芳基甲基哌嗪衍生物，其制备及其用途
GB0606876D0 (en) * 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
CN102065860A (zh) * 2008-05-20 2011-05-18 阿斯利康(瑞典)有限公司 治疗焦虑性重度抑郁障碍的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH583713A5 (is) 1973-06-29 1977-01-14 Cermol Sa
DE2900810A1 (de) 1979-01-11 1980-07-24 Cassella Ag Substituierte n-benzhydryl-n'-p- hydroxybenzyl-piperazine und verfahren zu ihrer herstellung
IT1140978B (it) 1980-05-23 1986-10-10 Selvi & C Spa 1-(4-clorobenzidril)-4-(2,3-diidros sipropil)-piperazina, metodi per la sua preparazione e relative composizione farmaceutiche
GB8320701D0 (en) 1983-08-01 1983-09-01 Wellcome Found Chemotherapeutic agent
IT1196150B (it) 1984-06-19 1988-11-10 Poli Ind Chimica Spa Derivati di 1-(bis-(4-fluorofenil)metil)-4-(3-fenil-2-propenil)-esaidro-1h-1,4-diazepina ad attivita' calcio antagonista,sua preparazione e composizioni che lo contengono
SE8500573D0 (sv) 1985-02-08 1985-02-08 Ferrosan Ab Novel piperazinecarboxamides having a phenoxyalkyl or thiophenoxyalkyl side chain
US5028610A (en) 1987-03-18 1991-07-02 Sankyo Company Limited N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
US4829065A (en) 1987-04-24 1989-05-09 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
IL96390A (en) 1989-11-22 1995-06-29 Janssen Pharmaceutica Nv Pharmacological preparations from the halls History of N-alkylpiperazinalalkanamide for the prevention or limitation of reproductive damage and some such new compounds and their preparation
US5574159A (en) 1992-02-03 1996-11-12 Delta Pharmaceuticals, Inc. Opioid compounds and methods for making therefor
US5681830A (en) 1992-02-03 1997-10-28 Delta Pharmaceuticals, Inc. Opioid compounds
US5807858A (en) 1996-06-05 1998-09-15 Delta Pharmaceutical, Inc. Compositions and methods for reducing respiratory depression
GB9202238D0 (en) 1992-02-03 1992-03-18 Wellcome Found Compounds
FR2696744B1 (fr) 1992-10-12 1994-12-30 Logeais Labor Jacques Dérivés de 2-pyrrolidone, leur procédé de préparation et leurs applications en thérapeutique.
JPH09501156A (ja) 1993-07-30 1997-02-04 ザ．ウェルカム．ファウンデーション．リミテッド 治療法で使用するピペラジン化合物
JP3352184B2 (ja) 1993-11-12 2002-12-03 株式会社アズウェル ピペラジン不飽和脂肪酸誘導体
US5693843A (en) * 1995-12-22 1997-12-02 E. I. Du Pont De Nemours And Company Process for hydrocyanation of diolefins and isomerization of nonconjugated 2 alkyl-3-monoalkenenitriles
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
SE9604786D0 (sv) 1996-12-20 1996-12-20 Astra Pharma Inc New compounds
CA2316341A1 (en) 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
SE9904674D0 (sv) * 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds

Also Published As

Publication number Publication date
AU2418401A (en) 2001-07-03
ATE275143T1 (de) 2004-09-15
RU2258703C2 (ru) 2005-08-20
BR0016591A (pt) 2002-09-10
US6680318B2 (en) 2004-01-20
BG65457B1 (bg) 2008-08-29
ES2225289T3 (es) 2005-03-16
PT1242410E (pt) 2004-12-31
DE60013486D1 (de) 2004-10-07
EP1242410B1 (en) 2004-09-01
EP1242410A1 (en) 2002-09-25
CA2395300A1 (en) 2001-06-28
KR20070090050A (ko) 2007-09-04
RU2002114343A (ru) 2004-01-10
SI1242410T1 (en) 2004-12-31
HK1048308B (zh) 2005-04-08
IL150125A0 (en) 2002-12-01
JP2003522741A (ja) 2003-07-29
AU780799B2 (en) 2005-04-21
US20040138225A1 (en) 2004-07-15
HUP0300020A3 (en) 2005-02-28
NO20022920D0 (no) 2002-06-18
ZA200204255B (en) 2003-08-28
DK1242410T3 (da) 2004-11-29
SE9904674D0 (sv) 1999-12-20
BG106805A (en) 2003-03-31
MXPA02006063A (es) 2003-02-06
NZ519986A (en) 2004-06-25
HK1048308A1 (en) 2003-03-28
IS2143B (is) 2006-09-15
US20030105110A1 (en) 2003-06-05
CZ20022124A3 (cs) 2002-11-13
KR100769814B1 (ko) 2007-10-23
WO2001046174A1 (en) 2001-06-28
HUP0300020A2 (en) 2003-05-28
SK8832002A3 (en) 2003-03-04
IL150125A (en) 2006-08-20
NO20022920L (no) 2002-07-22
PL356780A1 (en) 2004-07-12
NO322432B1 (no) 2006-10-02
EE200200337A (et) 2003-10-15
DE60013486T2 (de) 2005-11-17
UA71650C2 (uk) 2004-12-15
CN1608064A (zh) 2005-04-20
KR20020062350A (ko) 2002-07-25

Similar Documents

Publication Publication Date Title
IS2143B (is) Píperasínómetýlbensamíð sem delta-ópíóíðviðtakagerandefni
PT970095E (pt) Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
UA74443C2 (uk) Ліганди 5-нт рецептора та їх використання
ATE320436T1 (de) Dimere pyrrolobenzodiazepine
EA200201119A1 (ru) Лиганды меланокортиновых рецепторов
YU10602A (sh) Upotreba baff receptora imunoregulatornog agensa
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
EA200100315A1 (ru) Простые тетрагидропиридовые эфиры
BR0007864A (pt) Composto, e, uso de um composto
ATE326209T1 (de) Verminderung des haarwuchses
ATE332903T1 (de) Kondensierte pyridoindolderivate
CO5271666A1 (es) Derivados de pirimidina
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
PL340467A1 (en) Application of mithrazapin in treating apnoea dissomnia
EP1546182A4 (en) COMPOSITIONS AND METHOD FOR DIAGNOSING AND TREATING TUMORS
DE60112960D1 (de) Kondensierte pyridoindolderivate
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200100517A1 (ru) Антагонисты 5ht1 для антидепрессантной терапии
DE60008400D1 (de) Triazolopyrimidinderivate
UY26085A1 (es) N-[-(4-aminofenil)-2,3-dihidro-1,4-benzodioxina-2-metanamina su preparacion y su aplicacion en terapeutica
MXPA03003971A (es) Derivados de indol como inhibidores de pde5.
CY1105373T1 (el) Ισοκινολινυλικα καρβοξαμιδια και η χρηση τους ως αντισπαστικα
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR200103237T2 (tr) İmidazodiazepin türevi
ATE276363T1 (de) Metabolismuskontrolle mittels zusamensetzungen des humanen 2-oxoglutarat-trägers